Hadasit and Oramed Pharmaceuticals Collaborate for Development of Oral Delivery System Technology
Hadasit, the Hadassah University Medical Center's technology transfer company, has signed a contract with Oramed Pharmaceuticals to continue working together on the development of Oramed's platform technology for the oral delivery of medicine, such as insulin. Oramed, a publicly traded company, is the outgrowth of 30 years of research conducted at Hadassah, mainly by the late Prof. Chanoch Bar-On in the Diabetes Unit.
Oramed's flagship product is an oral insulin capsule, which is currently in Phase 2 clinical trials. The oral insulin capsule has the potential to change the current paradigm of treatment for the 285 million people suffering with diabetes worldwide.
Hadasit, Hadassah’s Technology Transfer Arm, Reviews
When the Hadassah University Medical Center’s physicians suggest a
solution to a medical problem which can lead to the development of a new
medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its
feasibility and supports the promotion of those viable ideas with innovation
potential. Although 2012 has been “a year full of challenges for the life
science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer,
Hadasit still signed 125 agreements for clinical trials, all to be done at
Hadassah. In addition, Hadasit signed 15 agreements for cooperation and
commercialization of technologies that were developed at Hadassah. Click here
to read the latest Newsletter from Hadasit >>